Study to Assess Tezampanel for Opioid Withdrawal Syndrome
Phase 1
40
about 1.1 years
18–65
1 site in IN
What this study is about
This trial is testing whether Tezampanel (TZP) can help with opioid withdrawal syndrome in people who have opioid use disorder. Participants will receive either TZP or a placebo daily for 7 days during their stay at the research center.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Placebo
- 2.Take Tezampanel
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: To evaluate systemic tolerability and safety of intravenous tezampanel administration.
Secondary: To characterize Area Under the Curve (AUC) concentration of tezampanel, To characterize Cmax (maximum concentration) of tezampanel
Psychiatry / Mental Health